HealthMore in Health →
Pfizer Secures Obesity Drug Approval in China
Pfizer has won approval for a GLP-1 obesity drug in China shortly after licensing the shot from Hangzhou-based Sciwind Biosciences.
Key Takeaways
- Pfizer wins China approval for GLP-1 obesity shot licensed from Sciwind
- Enters market where obesity affects over half of Chinese adults
DE
DT Editorial AI··3 min read·via endpoints.news